Matches in Nanopublications for { ?s ?p ""Ibandronate sodium is contraindicated in patients with the following conditions: * Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia (see Warnings and Precautions [ 5.1 * Inability to stand or sit upright for at least 60 minutes (see Dosage and Administration [2.2], and Warnings and Precautions [ 5.1 * Hypocalcemia (see Warnings and Precautions [ 5.2 * Known hypersensitivity to ibandronate sodium tablets or to any of its excipients. Cases of anaphylaxis have been reported. (see Adverse Reactions [6.2]) * Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia ( 4 5.1 * Inability to stand or sit upright for at least 60 minutes ( 4 5.1 * Hypocalcemia ( 4 * Hypersensitivity to ibandronate sodium ( 4"" ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- association label ""Ibandronate sodium is contraindicated in patients with the following conditions: * Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia (see Warnings and Precautions [ 5.1 * Inability to stand or sit upright for at least 60 minutes (see Dosage and Administration [2.2], and Warnings and Precautions [ 5.1 * Hypocalcemia (see Warnings and Precautions [ 5.2 * Known hypersensitivity to ibandronate sodium tablets or to any of its excipients. Cases of anaphylaxis have been reported. (see Adverse Reactions [6.2]) * Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia ( 4 5.1 * Inability to stand or sit upright for at least 60 minutes ( 4 5.1 * Hypocalcemia ( 4 * Hypersensitivity to ibandronate sodium ( 4"" assertion.